In GEPIA datasets, higher BTN3A1 expression was associated with longer overall survival in patients with BLCA, mesothelioma (MESO), KIRC, and skin cutaneous melanoma (SKCM) (Fig. 2D), whereas higher BTN3A1 expression was associated with worse prognosis in patients with brain lower grade glioma (LGG) (Fig. 2E). Here, BTN3A1 is linked to bladder transitional cell carcinoma.